Healthcare / Medical DevicesNasdaqCM
$9.72
-0.12 (-1.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $11.9M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$373M
P/E
26.3x
↑EV/EBITDA
7.2x
↓ROE
10.6%
↑Gross Margin
57.5%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+22.7%
FCF CAGR
-4.3%
FCF margin
4.4%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $270.3M · net income $14.9M · FCF $11.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $270.3M | $270.3M | $224.3M | $183.0M | $138.8M | $117.1M | $131.3M | $80.3M | $64.5M |
| Net Income | $14.9M | $14.9M | $11.3M | $10.2M | $6.2M | $9.1M | $31.5M | $8.5M | $9.5M |
| EBITDA | $51.6M | $51.6M | $42.3M | $36.7M | $24.8M | — | — | — | — |
| EPS | — | — | 0.28 | 0.25 | 0.16 | 0.22 | 0.78 | 0.21 | 0.24 |
| Gross Margin | 57.5% | 57.5% | 59.4% | 61.6% | 61.0% | 62.7% | 61.0% | 69.8% | 74.1% |
| Operating Margin | 7.7% | 7.7% | 7.1% | 8.2% | 6.2% | 9.9% | 20.4% | 11.0% | 15.6% |
| Net Margin | 5.5% | 5.5% | 5.0% | 5.6% | 4.5% | 7.8% | 24.0% | 10.6% | 14.7% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.11 | 0.11 | 0.05 | 0.09 | 0.01 | 0.05 | 0.07 | 0.17 | 0.00 |
| Current Ratio | 1.22 | 1.22 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $11.9M | $11.9M | $1.3M | $19.1M | $4.8M | $2.8M | $22.1M | $5.7M | $16.3M |
| Returns | |||||||||
| ROE | 10.6% | 10.6% | 8.6% | 9.0% | 6.4% | 9.6% | 38.6% | 19.5% | 29.2% |
| Valuation | |||||||||
| P/E | 26.27 | 26.27 | 29.00 | 29.36 | 48.88 | — | — | — | — |
| EV/EBITDA | 7.21 | 7.21 | 7.58 | 8.01 | 11.89 | — | — | — | — |
| P/B | 2.61 | 2.61 | 2.52 | 2.60 | 3.21 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 20.5% | 20.5% | 22.5% | 31.8% | — | -10.8% | 63.6% | 24.5% | — |
| EPS Growth | — | — | 12.0% | 56.3% | — | -71.8% | 271.4% | -12.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+46.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.28 → n/d
Residual
+46.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.